> Details

Raskovalova, Tatiana; Twerenbold, Raphael; Collinson, Paul O; Keller, Till; Bouvaist, Hélène; Folli, Christian; Giavarina, Davide; Lotze, Ulrich; Eggers, Kai M; Dupuy, Anne-Marie; Chenevier-Gobeaux, Camille; Meune, Christophe; Maisel, Alan; Mueller, Christian; Labarère, José

Diagnostic accuracy of combined cardiac troponin and copeptin assessment for early rule-out of myocardial infarction: a systematic review and meta-analysis

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Diagnostic accuracy of combined cardiac troponin and copeptin assessment for early rule-out of myocardial infarction: a systematic review and meta-analysis
  • Contributor: Raskovalova, Tatiana; Twerenbold, Raphael; Collinson, Paul O; Keller, Till; Bouvaist, Hélène; Folli, Christian; Giavarina, Davide; Lotze, Ulrich; Eggers, Kai M; Dupuy, Anne-Marie; Chenevier-Gobeaux, Camille; Meune, Christophe; Maisel, Alan; Mueller, Christian; Labarère, José
  • imprint: Oxford University Press (OUP), 2014
  • Published in: European Heart Journal: Acute Cardiovascular Care
  • Language: English
  • DOI: 10.1177/2048872613514015
  • ISSN: 2048-8734; 2048-8726
  • Origination:
  • Footnote:
  • Description: <jats:sec><jats:title>Aims:</jats:title><jats:p> This systematic review aimed to investigate the diagnostic accuracy of combined cardiac troponin (cTn) and copeptin assessment in comparison to cTn alone for early rule-out of acute myocardial infarction (AMI). </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> Primary studies were eligible if they evaluated diagnostic accuracy for cTn with and without copeptin in patients with symptoms suggestive of AMI. AMI was defined according to the universal definition, using detection of cTn as a marker for myocardial necrosis. Eligible studies were identified by searching electronic databases (Medline, EMBASE, Science Citation Index Expanded, CINAHL, Pascal, and Cochrane) from inception to March 2013, reviewing conference proceedings and contacting field experts and the copeptin manufacturer. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> In 15 studies totalling 8740 patients (prevalence of AMI 16%), adding copeptin improved the sensitivity of cTn assays (from 0.87 to 0.96, p=0.003) at the expense of lower specificity (from 0.84 to 0.56, p&lt;0.001). In 12 studies providing data for 6988 patients without ST-segment elevation, the summary sensitivity and specificity estimates were 0.95 (95% CI 0.89 to 0.98) and 0.57 (95% CI 0.49 to 0.65) for the combined assessment of cTn and copeptin. When a high-sensitivity cTnT assay was used in combination with copeptin, the summary sensitivity and specificity estimates were 0.98 (95% CI 0.96 to 1.00) and 0.50 (95% CI 0.42 to 0.58). </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> Despite substantial between-study heterogeneity, this meta-analysis demonstrates that copeptin significantly improves baseline cTn sensitivity. Management studies are needed to establish the effectiveness and safety of measuring copeptin in combination with high-sensitivity cTnT for early rule-out of AMI without serial testing. </jats:p></jats:sec>
  • Access State: Open Access